Zoetis Inc. (ZTS)

Zoetis Inc. is a global leader in the animal health industry, engaged in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions. Incorporated in Delaware in 2012 as a spin-off from Pfizer Inc., the company serves customers—including veterinarians, pet owners, livestock farmers, and ranchers—across eight core species, divided into companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). Its portfolio spans seven major product categories: parasiticides, vaccines, dermatology, other pharmaceuticals (pain, sedation, reproductive, oncology), anti-infectives, animal health diagnostics, and medicated feed additives, along with nutritionals, biodevices, and genetic testing services, comprising approximately 300 product lines.

Zoetis operates through two reportable segments, United States (53% of 2023 revenue) and International (46%), with companion animal products representing about 65% of revenue and livestock products about 34%, while contract manufacturing (through its Client Supply Services organization) and human health products make up the remainder. Key brands include Simparica/Simparica Trio and Apoquel for parasiticide and dermatology treatment in dogs, Cytopoint for allergic dermatitis, Revolution/Revolution Plus/Stronghold for parasite protection, the ceftiofur anti-infective line for livestock, Draxxin for bovine and swine respiratory disease, and vaccine franchises such as Vanguard, Fostera, Suvaxyn, and Rispoval/Bovishield, along with newer therapies like Librela and Solensia for osteoarthritis pain management via monoclonal antibodies. The company also has a growing diagnostics business anchored by its VetScan portfolio, Witness, Serelisa, and ProFlok immunodiagnostic kits, and the Vetscan Imagyst AI-powered diagnostic platform, built in part through acquisitions such as Abaxis, Phoenix Central Laboratory, ZNLabs, and Ethos Diagnostic Science.

Additional acquisitions have expanded its capabilities in animal nutrition (Platinum Performance), companion animal genetics (Basepaws), livestock and companion animal products in Australia (Jurox), and antibody-based therapeutics research (PetMedix, adivo GmbH). Zoetis also maintains a leading position in aquatic health through its Pharmaq business, offering vaccines and parasiticides for salmon farming. The company markets its products directly in about 45 countries and sells in more than 100 countries worldwide, with significant presence in both developed markets (U.S., Australia, Canada, various European countries, Japan) and emerging markets (Brazil, Chile, China, Mexico), which together contributed roughly 21% of 2023 total revenue.

Growth in the companion animal sector is driven by rising pet ownership, disposable income, and the deepening human-animal bond, while livestock demand is fueled by global population growth, food security needs, and the push for sustainable, high-quality animal protein production.